Medical device maker Dexcom topped Wall Street estimates for third-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring systems.

Q3 2025 Earnings Call Transcript October 30, 2025 DexCom, Inc. beats earnings expectations. Reported EPS is $0.61, expectations were $0.57. Operator: Ladies and gentlemen, welcome to the DexCom Third ...

Fintel reports that on October 31, 2025, Wells Fargo maintained coverage of DexCom (NasdaqGS:DXCM) with a Overweight ...

DexCom receives a BUY rating due to strong growth, expanding margins, and the launch of Stelo, the first OTC CGM for non-insulin users. DXCM raised its 2025 outlook, targeting $4.6B+ in revenue, 62% ...

If you’re trying to figure out whether now’s the time to buy, hold, or even sell DexCom stock, you’re not alone. After all, its share price has been a bit of a roller coaster lately. Over the last ...

Earlier this month, DexCom reported stronger-than-expected second quarter revenues but issued the weakest full-year outlook among patient monitoring peers, following a sector-wide selloff triggered by ...

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include ...

Dexcom (Nasdaq:DXCM) shares took a hit after hours today on third-quarter results that came in ahead of the consensus ...

Amid some scrutiny over its latest-generation G7 CGM, Dexcom officials addressed claims on the company's latest earnings call ...